Phylos® and People Science® Announce Results of IRB-Backed Controlled Research Study on the Energizing Effects of THCV
PORTLAND, Ore., Feb. 27, 2024 /PRNewswire/ -- Cannabis genetics company Phylos®, along with People Science, a direct-to-consumer scientific research and technology company, has conducted an IRB-approved, double-blind clinical research study on the effects of rare cannabinoid tetrahydrocannabivarin (THCV). Results of the study found that Natural Natural™ THCV by Phylos significantly increased energy, activity, motivation, and well-being compared to placebo, without the fatigue and munchies associated with THC consumption.
- Results of the study found that Natural Natural ™ THCV by Phylos significantly increased energy, activity, motivation, and well-being compared to placebo, without the fatigue and munchies associated with THC consumption.
- "This study signifies a pivotal moment for the cannabis industry in understanding the effect of THCV in combination with THC," according to Alisha Holloway, PhD, Chief Scientific Officer at Phylos.
- "The Natural Natural THCV study allows us to leverage our exceptional plants in the advancement of targeted cannabis products, and to chart new territories in understanding the efficacy of natural cannabinoids."
- Research participants ingested unmedicated placebo gummies, THC-only gummies, and gummies infused with extract from Get Sh!t Done™ (GSD), a THCV-dominant plant bred by Phylos.